Exploring Galectin‑3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular...

Area of Science:

• Biomarkers and Cardiovascular Research
• Galectin-3 in Atherosclerosis and Heart Failure

Background:

• Galectin-3 (Gal-3) is a key biomarker candidate for cardiovascular and cerebrovascular diseases.
• Gal-3 plays a multifaceted role in atherosclerosis, including disease progression and outcome prediction.

Purpose of the Study:

• To reanalyze clinical trials involving Gal-3 as a measure or outcome.
• To synthesize current understanding and guide future clinical applications of Gal-3.

Main Methods:

• Reanalysis of existing clinical trials utilizing Gal-3.
• Synthesis of data on Gal-3 associations with clinical factors and pathophysiological processes.

Main Results:

• Gal-3 is associated with various clinical factors, pathophysiological processes, and critical outcomes.
• Elevated Gal-3 levels show synergy with established heart failure diagnostic measures.

Conclusions:

• Standardized methodology is crucial for consistent Gal-3 research.
• Further research can enhance the clinical application of Gal-3 in cardiovascular and cerebrovascular disease management.